The Longevity Peptides That Show Up in Every Bryan Johnson and Peter Attia Conversation (And What the Human Evidence Actually Shows)
A pseudonymous reader walks through the molecules that keep getting named in the public longevity conversation, with the human-trial evidence beside each one and an honest grade per peptide.
by JoyBoy
14 min read
Last reviewed May 2026
Mixed across molecules
Mixed across molecules
Why I looked into this
If you have spent any time in the longevity corner of the internet in the last two years, you have heard the same handful of peptide names recycled across every podcast clip, blog post, and short-form video. Bryan Johnson’s content and Peter Attia’s content have done a lot of work to popularize that conversation, and the conversation has spilled out far past either of them. The names get repeated. The evidence does not always travel with them.
I want to be careful and explicit. I am not claiming what either of those two people personally uses. I have not interviewed them. I am not in their group chats. What I am writing about is the public conversation they helped seed, the molecules that get named in that conversation, and what the actual human research says about each one when you go look it up.
I read the published trials, the regulatory documents, and the review articles for each peptide on this list. I am not summarizing animal data as evidence. The point of this piece is to show how unevenly the evidence is distributed across the molecules people talk about as if they were a single category.
Scope and naming
Before the evidence walk, two scope notes worth getting out of the way.
NMN and NR are not peptides. They are NAD+ precursors, small molecules in the nicotinamide family. They get bundled into the “longevity peptide” conversation constantly because they share the same audience, but they are a different chemical category and a different regulatory category. I cover them briefly in the research section because they keep coming up, but the evidence framing is different. If a piece of content is calling NMN a peptide, that piece of content has not done its homework.
“Longevity” is not a clinical endpoint. Nobody runs an RCT with “lived longer” as the primary outcome on a reasonable timeline. What you actually get in the human literature is surrogate endpoints: weight, blood pressure, lipids, glucose, body composition, immune markers, sometimes cognition. The honest longevity argument runs through those surrogates. The dishonest one skips them.
What the human research shows, peptide by peptide
Which of these molecules actually have human RCTs?
Three categories with real Phase 3 human evidence, two with smaller real evidence, two with effectively none.
- Semaglutide and Tirzepatide (🟢 Human RCT). Multiple Phase 3 RCTs each, total enrolled across the pivotal obesity programs is well into five figures. The longevity argument here runs through cardiovascular outcomes (Lincoff et al, NEJM 2023, SELECT, ~17,604 participants, ~20% reduction in the major adverse cardiovascular event composite for Semaglutide). The Tirzepatide cardiovascular outcomes trial (SURPASS-CVOT) is in flight. Industry funded.
- Tesamorelin (🟢 Human RCT). FDA-approved for HIV-associated lipodystrophy on the basis of two Phase 3 RCTs (Falutz et al, NEJM 2007, n=412 across the program). Reduces visceral adipose tissue. The off-label longevity marketing extrapolates from the visceral fat reduction. The trials measured visceral fat reduction in a specific HIV population. Those are not the same claim. Industry funded.
- Thymosin Alpha-1 (🟢 Human RCT, mostly outside the US). Multiple RCTs across hepatitis B, sepsis, and oncology supportive care, mostly run in China and Europe. Approved in roughly 35 countries. Not approved by the FDA. The immune-support framing in the longevity space is loosely related to the actual indications studied.
Which have smaller human data, and what is wrong with it?
Two molecules in this middle bucket.
- Epitalon (🟡 Human Observational). A short tetrapeptide developed in Russia in the 1980s. The human data exists, but it is almost entirely Russian-language observational work in elderly populations from a single research group (Khavinson and colleagues). The methodology is not what a Western RCT reviewer expects: small samples, open-label designs, surrogate endpoints, and almost no independent replication. The molecule may do something. The published evidence is not strong enough to tell you what.
- NMN and NR (🟡 Human Observational, with some small RCTs). Several small placebo-controlled human trials exist, mostly measuring NAD+ levels in blood as the primary endpoint. NAD+ levels do rise. Whether that translates to any of the harder endpoints longevity content claims is still an open question in the literature. The aging-clock and healthspan extrapolations are not what these trials measured. Reviewing my own scope rule: these are not peptides. I include them only because the longevity conversation puts them in the same bucket.
What about BPC-157 and MOTS-c?
Both of these get talked about as if the human evidence is in the same room as the rodent evidence. It is not.
- BPC-157 (🔴 No Human Trials). Zero published RCTs in humans. The longevity and healing claims travel almost entirely on rodent data and on internet anecdotes. I have used it personally for a shoulder injury and write about that experience in its own monograph. That is opinion, not evidence, and it is fenced as opinion. It does not change the grade.
- MOTS-c (🔴 No Human Trials). A mitochondrial-derived peptide identified in 2015. The metabolic and exercise-mimetic story is built almost entirely from animal work. As of writing, no published human RCTs exist. The longevity marketing is the largest gap between hype and human evidence on this entire list.
Where the longevity-peptide hype came from
The pattern is consistent across most of these molecules. A small early human or animal signal generates an idea. The idea gets picked up by a podcast or a long-form blog post in the longevity space. The signal in the original paper gets extrapolated past what the methodology supports. By the time the third or fourth person summarizes it, the qualifier has fallen off the front of the sentence.
This is not a Bryan-Johnson or Peter-Attia-specific phenomenon. It is how the longevity content ecosystem works. Both of them, to be fair, are usually more careful about the qualifiers than the people summarizing them. The summary downstream is what loses the nuance, and the audience that sees the summary often does not know what the original paper actually said.
The other pattern is that “longevity” gets used as a flexible umbrella for whatever the molecule’s most attractive secondary effect happens to be. Tesamorelin reduces visceral fat, so it gets called longevity. Semaglutide reduces cardiovascular events, so it gets called longevity. BPC-157 has rodent gut and tissue data, so it gets called longevity. The label travels easily because it is vague.
FDA and legal status
Semaglutide (Ozempic, Wegovy, Rybelsus). Tirzepatide (Mounjaro, Zepbound). Tesamorelin (Egrifta) for HIV-associated lipodystrophy.
Thymosin Alpha-1 (Zadaxin) is approved in roughly 35 countries for hepatitis B, hepatitis C, and adjunctive oncology indications. Not approved in the US.
Epitalon, BPC-157, MOTS-c are not approved by any major regulator for any indication. Five of the seven peptides on the FDA’s July 2026 PCAC review list show up in this longevity conversation, which tells you something about how the regulatory conversation is catching up.
NMN and NR are small molecules. NMN’s regulatory status as a dietary supplement was challenged by the FDA in 2022 and remains contested. NR is sold widely as a supplement.
The honest summary: the molecules in this list with the strongest human evidence are also the ones with the cleanest regulatory status. The molecules with the loudest longevity marketing are the ones with neither approval nor robust human data. That correlation is not a coincidence.
I built a doctor visit-prep one-pager for the longevity-peptide conversation specifically. Evidence summary, what to ask, and the gaps the marketing skips. Free PDF. No upsell.
Get the longevity visit-prep one-pagerHow to evaluate a source: the safety framework
Why this section exists: people are going to look for sources whether I help or not. My goal here is harm reduction, not facilitation. I do not name sellers. I do not link to anyone. I am teaching you how to think about a source so you can have an informed conversation with a clinician.
Green flags
- For the FDA-approved molecules: a real prescription from a clinician you can talk to, filled at a licensed pharmacy
- For Thymosin Alpha-1: a clinician operating within the 503A compounding framework, not a research-chemical seller
- A clinician who will say “this is not a good fit for you” and walk away
- Disclosure of where a compounded product is synthesized and independently tested
- Honest acknowledgment that the longevity marketing is downstream of the actual indication
Red flags
- “Research use only” labels on a vial being marketed for human use
- Anyone selling Epitalon, BPC-157, or MOTS-c as a finished consumer product for longevity
- Marketing copy that conflates rodent results with human evidence
- Urgency or scarcity language (“last batch”, “before the FDA shuts it down”)
- Refusal to provide independent third-party lab testing
The wrinkle for the longevity space specifically
The longevity audience is unusually receptive to claims that outpace evidence, because the audience is unusually motivated. That motivation is exactly what bad sellers know how to monetize. The same molecule sold to a clinician under a 503A compounding framework and sold to a forum reader under a “research use only” label is, on paper, the same chemical structure. In practice, the synthesis, purity, sterility, and excipient handling can be entirely different. You are paying the licensed pharmacy for that difference. You are paying the gray-market seller for the absence of that difference.
Cost reality
The list price of FDA-approved Semaglutide and Tirzepatide is high, and insurance coverage for off-label longevity use is functionally zero. Tesamorelin is expensive even on-label. Thymosin Alpha-1 is not legally available in the US outside the 503A compounding pathway. The unapproved molecules (Epitalon, BPC-157, MOTS-c) are cheap because there is no pharmaceutical-quality production of them, and that is the cost being shifted to you in a different form.
Questions worth asking any source
Where is this synthesized? Where is it independently tested? What is the chain of custody? Who is the prescribing clinician of record? What happens if I have a reaction? A real source has answers. A bad one has marketing copy and a “research use only” sticker.
My 503A Source-Safety Checklist is the single most useful tool on this site. Free PDF. No upsell. It is what I use myself.
Download the source-safety checklistMy honest take
This section is opinion, not evidence. I am not endorsing use of any of these peptides. Everything above this line is sourced from published human research and regulatory documents. Everything below is my personal perspective as one pseudonymous reader. It is not medical advice. Your situation is not my situation. Do not treat this as a recommendation to try anything.
The thing that bothers me about the longevity-peptide conversation is not that it exists. It is that the molecules with the strongest human evidence and the molecules with the loudest marketing are almost in inverse order. Semaglutide has thousands of patient-years of cardiovascular outcomes data. MOTS-c has a single-digit count of human anything. The internet talks about them as if they belong in the same sentence.
“The molecules with the strongest human evidence and the loudest longevity marketing are almost in inverse order. That is the pattern, and it is the pattern most of this content hides.”
If I had to summarize the public-figure dynamic, my honest reading is this. Both Bryan Johnson and Peter Attia spend more time than the average influencer naming their qualifiers. The downstream content that re-summarizes them does not. By the time a clip has been clipped twice and tweeted three times, “Tesamorelin reduced visceral adipose tissue in a Phase 3 trial in a specific HIV-associated lipodystrophy population” has become “Tesamorelin is a longevity peptide.” Those are not the same sentence, and the difference is most of the integrity of the conversation.
“If a molecule’s longevity story requires you to skip past the actual indication it was studied for, that is not a longevity story. That is marketing.”
If a friend asked me how to think about this list, I would say: take the metabolic GLP-1 case seriously, because the cardiovascular outcomes data is real and the longevity argument runs through it cleanly. Take Tesamorelin and Thymosin Alpha-1 as molecules with real human RCTs for specific indications and a longevity story that is loose extrapolation. Treat Epitalon and the NAD+ precursors as interesting hypotheses with thin or methodologically suspect human data. Treat BPC-157 and MOTS-c as zero-human-evidence molecules whose longevity reputations are entirely forum-derived. None of that means none of these molecules will turn out to do something. It means the evidence today does not support the confidence today.
Questions to ask your doctor
If you are considering any of the molecules on this list because of something you heard in the longevity conversation, here are the questions I would want answered before walking out of the appointment.
- What is the actual indication this molecule was studied for, and how does my situation compare to that population? Most longevity uses are off-label extrapolations from a specific clinical population. The further you are from that population, the weaker the inference.
- What level of human evidence exists, and what is the trial design behind it? Phase 3 RCT, Phase 2 RCT, observational, case series, or zero. The honest answer is one of those five and should be the first sentence of the conversation.
- Are we using an FDA-approved product, a 503A-compounded product, or something else? The answer changes the source-safety conversation completely.
- What are the surrogate endpoints we would actually monitor? Visceral fat, lipids, glucose, body composition, immune markers, sleep, and so on. Longevity is not a clinical endpoint. The surrogates are.
- What is your stop condition? Under what circumstance would you discontinue, and what would the off-ramp look like? A clinician without a written stop condition is a clinician without a plan.
- What does the literature actually say versus what the longevity content I read implied? A clinician who has read the source papers can answer this in one sentence. A clinician who is repeating podcast summaries cannot.
I built a peptide-specific visit-prep packet to take into your appointment. Evidence summary, doctor questions, space for notes. Free PDF.
Get the visit-prep packetWhat to do next
If you are curious
Read the individual monographs for each molecule on this list. The evidence walks vary enormously, and a single feature article cannot replace the molecule-specific reading.
Browse the monographs →If you are considering
Have the conversation with a clinician you can actually reach. Bring the visit-prep packet. Bring the actual indication. Bring your stop condition before you start.
Get the visit-prep packet →If you have decided
Use the source-safety checklist before committing to any provider or pharmacy. The longevity-peptide market is the segment where source quality varies the most.
Download the source-safety checklist →Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002. Industry funded (Novo Nordisk).
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232. Industry funded (Novo Nordisk).
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. Industry funded (Eli Lilly).
- Falutz J, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. N Engl J Med. 2007;357:2359-2370. Industry funded (Theratechnologies).
- US FDA. Egrifta (tesamorelin) prescribing information.
- Garaci E, et al. Thymosin Alpha-1: from bench to bedside. Annals of the New York Academy of Sciences. Multiple reviews. Mixed funding.
- Khavinson VKh, et al. Peptide Epitalon improves age-related changes in elderly populations. Russian-language journals, observational designs, single research group. Funding largely institutional.
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metabolism. 2015. Animal data only as of writing.
- US FDA. July 2026 Pharmacy Compounding Advisory Committee briefing materials, docket FDA-2025-N-6895.
- US FDA. Notices regarding the resolution of Semaglutide and Tirzepatide drug shortage status, 2024 to 2025.
Funding for the pivotal trials of the FDA-approved molecules is largely industry. That is worth saying plainly. Industry funding does not invalidate the data, but it is part of how the data should be read. The Russian-language Epitalon literature comes overwhelmingly from one research group, which is a separate methodological caveat.
Related monographs
Semaglutide
The metabolic-longevity case in the cleanest form. Multiple Phase 3 programs, cardiovascular outcomes data.
BPC-157
The forum-famous healing peptide with zero human RCTs. Why the rodent data does not transfer.
MOTS-c
The mitochondrial-derived peptide with the largest gap between marketing and human evidence on this list.
The Peptide File provides educational content based on published research. This article is not medical advice. The Peptide File does not sell, distribute, or facilitate the purchase of any peptide compound. Always work with a qualified healthcare provider.